title: Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference.
abstract: EUROPRISE is a Network of Excellence sponsored from 2007 to 2011 by the European Commission within the 6th Framework Program. The Network encompasses a wide portfolio of activities ranging from an integrated research program in the field of HIV vaccines and microbicides to training, dissemination and advocacy. The research program covers the whole pipeline of vaccine and microbicide development from discovery to early clinical trials. The Network is composed of 58 partners representing more than 65 institutions from 13 European countries; it also includes three major pharmaceutical companies (GlaxoSmithKline, Novartis and Sanofi-Pasteur) involved in HIV microbicide and vaccine research. The Network displays a dedicated and informative web page: http://www.europrise.org. Finally, a distinguishing trait of EUROPRISE is its PhD School of students from across Europe, a unique example in the world of science aimed at spreading excellence through training. EUROPRISE held its second annual conference in Budapest in November, 2009. The conference had 143 participants and their presentations covered aspects of vaccine and microbicide research, development and discovery. Since training is a major task of the Network, the students of the EUROPRISE PhD program summarized certain presentations and their view of the conference in this paper.
authors.affiliation: Karolinska Institute, Stockholm, Sweden.
authors.forename: Britta
authors.initials: B
authors.lastname: Wahren
authors.forename: Priscilla
authors.initials: P
authors.lastname: Biswas
authors.forename: Marie
authors.initials: M
authors.lastname: Borggren
authors.forename: Adam
authors.initials: A
authors.lastname: Coleman
authors.forename: Kelly
authors.initials: K
authors.lastname: Da Costa
authors.forename: Winni
authors.initials: W
authors.lastname: De Haes
authors.forename: Tessa
authors.initials: T
authors.lastname: Dieltjens
authors.forename: Stefania
authors.initials: S
authors.lastname: Dispinseri
authors.forename: Katrijn
authors.initials: K
authors.lastname: Grupping
authors.forename: David
authors.initials: D
authors.lastname: Hallengärd
authors.forename: Julia
authors.initials: J
authors.lastname: Hornig
authors.forename: Katja
authors.initials: K
authors.lastname: Klein
authors.forename: Lara
authors.initials: L
authors.lastname: Mainetti
authors.forename: Paolo
authors.initials: P
authors.lastname: Palma
authors.forename: Marc
authors.initials: M
authors.lastname: Reudelsterz
authors.forename: Janna
authors.initials: J
authors.lastname: Seifried
authors.forename: Philippe
authors.initials: P
authors.lastname: Selhorst
authors.forename: Annette
authors.initials: A
authors.lastname: Sköld
authors.forename: Hannes
authors.initials: H
authors.lastname: Uchtenhagen
authors.forename: Marit J
authors.initials: MJ
authors.lastname: van Gils
authors.forename: Caroline
authors.initials: C
authors.lastname: Weber
authors.forename: Robin
authors.initials: R
authors.lastname: Shattock
authors.forename: Gabriella
authors.initials: G
authors.lastname: Scarlatti
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D056704:Adaptive Immunity / Q000276:immunology; D000818:Animals; D000890:Anti-Infective Agents / Q000138:chemical synthesis*; D002986:Clinical Trials as Topic; D004198:Disease Susceptibility; D015195:Drug Design; D005060:Europe; D015658:HIV Infections / Q000276:immunology; D015497:HIV-1 / Q000276:immunology; D006801:Humans; D018928:Immunity, Mucosal / Q000276:immunology; D051379:Mice; D009500:Neutralization Tests
chemical_list: D016915:AIDS Vaccines; D000890:Anti-Infective Agents